1. Home
  2. RNTX vs EUDA Comparison

RNTX vs EUDA Comparison

Compare RNTX & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.60

Market Cap

57.8M

Sector

Health Care

ML Signal

N/A

Logo EUDA Health Holdings Limited

EUDA

EUDA Health Holdings Limited

N/A

Current Price

$14.00

Market Cap

52.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
EUDA
Founded
2001
2021
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
52.8M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
RNTX
EUDA
Price
$0.60
$14.00
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $6.00
N/A
AVG Volume (30 Days)
★ 400.4K
51.9K
Earning Date
11-17-2026
12-19-2023
Dividend Yield
N/A
N/A
EPS Growth
★ 44.16
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$299.28
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.33
52 Week High
$2.10
$25.70

Technical Indicators

Market Signals
Indicator
RNTX
EUDA
Relative Strength Index (RSI) 41.56 43.20
Support Level $0.54 $12.52
Resistance Level $0.87 $18.36
Average True Range (ATR) 0.07 1.53
MACD 0.00 -0.03
Stochastic Oscillator 29.67 24.71

Price Performance

Historical Comparison
RNTX
EUDA

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About EUDA EUDA Health Holdings Limited

EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.

Share on Social Networks: